The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis
Abstract
Summary: Platelets are central mediators of haemostasis at sites of vascular injury, but they also mediate pathologic thrombosis. Activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion, promoting atherothrombotic disease. They also interact with endothelial cells and leukocytes to promote inflammation, which contributes to atherosclerosis. Multiple pathways contribute to platelet activation, and current oral antiplatelet therapy with aspirin and a P2Y12 adenosine diphosphate (ADP) receptor antagonist target the thromboxane A2 and ADP pathways, respectively. Both can diminish activation by other factors, but the extent of their effects depends upon the agonist, agonist strength, and platelet reactivity status. Although these agents have demonstrated significant clinical benefit, residual morbidity and mortality remain high. Neither agent is effective in inhibiting thrombin, the most potent platelet activator. This lack of comprehensive inhibition of platelet function allows continued thrombus formation and exposes patients to risk for recurrent thrombotic events. Moreover, bleeding risk is a substantial limitation of antiplatelet therapy, because these agents target platelet activation pathways critical for both protective haemostasis and pathologic thrombosis. Novel antiplatelet therapies that provide more complete inhibition of platelet activation without increasing bleeding risk could considerably decrease residual risk for ischemic events. Inhibition of the protease-activated receptor (PAR)-1 platelet activation pathway stimulated by thrombin is a novel, emerging approach to achieve more comprehensive inhibition of platelet activation when used in combination with current oral antiplatelet agents. PAR-1 inhibition is not expected to increase bleeding risk, as this pathway does not interfere with haemostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“anti-platelet agents are a cornerstone of current pharmacological interventions for the treatment and prevention of acute complications of CVD. These interventions are, however, hampered by their potential for bleeding as a complication”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Jennings, 2009
In the citing paper
“Use of antiplatelet agents has become a cornerstone for the treatment of CVD because of substantial reduction in CVD events and mortality37,38. However, more widespread use of antiplatelet agents has been limited by the increased risk of bleeding, which also leads to nonadherence39–41.”
From Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential (2018) · cites this paper as [39]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Vu, T.-K. H., Hung, D. T., Wheaton, V. I., & Coughlin, S. R. (1991) · Cell · doi:10.1016/0092-8674(91)90261-v · Cited by 2,970
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Cited by
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications
Andrabi, S. M., Sharma, N. S., Karan, A., Shahriar, S. M. S., Cordon, B., Ma, B., & Xie, J. (2023) · Advanced Science · doi:10.1002/advs.202303259 · Cited by 602
Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential
Roberts, A. B., Gu, X., Buffa, J. A., Hurd, A. G., Wang, Z., Zhu, W., Gupta, N., Skye, S. M., Cody, D. B., Levison, B. S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0128-1 · Cited by 552
Xing, L., Zhang, H., Qi, R., Tsao, R., & Mine, Y. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b06146 · Cited by 543
Metadata
- Authors
- Jennings, L.
- Affiliations
- University of Tennessee Health Science Center (US)
- Corresponding author
- Jennings, Lisa
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2009
- Volume
- 102
- Issue
- 08
- Pages
- 248-257
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2071461268
- Cited by
- 436
- References
- 85
- Citations by year
- 2026: 5 · 2025: 21 · 2024: 26 · 2023: 26 · 2022: 25 · 2021: 25 · 2020: 23 · 2019: 27 · 2018: 22 · 2017: 21 · 2016: 25 · 2015: 30 · 2014: 35 · 2013: 33 · 2012: 26
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- platelet activation, atherothrombosis, antiplatelet therapy, thrombin, protease-activated receptor 1, thromboxane A2, P2Y12 receptor, aspirin, bleeding risk, thrombus formation
- MeSH terms
- Animals, Blood Coagulation, Blood Platelets, Hemostasis, Humans, Inflammation, Leukocytes, Models, Biological, Platelet Aggregation Inhibitors, Thrombosis, Signal Transduction, Platelet Activation, Receptor, PAR-1, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. https://app.cochat.ai/papers/10.1160/th09-03-0192
- The paper
- Jennings, L. (2009). Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thrombosis and Haemostasis. https://doi.org/10.1160/th09-03-0192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.